17th Apr 2018 13:20
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Ms E Walmsley | ||||||||
b) | Position/status | Chief Executive Officer | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
16,583.050 £14.296
| ||||||||
e) | Date of the transaction | 2018-04-12 | ||||||||
f) | Place of the transaction | London Stock Exchange (XLON) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr R G Connor | ||||||||
b) | Position/status | President, Global Manufacturing & Supply | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
6,950.178 £14.296
| ||||||||
e) | Date of the transaction | 2018-04-12 | ||||||||
f) | Place of the transaction | London Stock Exchange (XLON) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr L Debruyne | ||||||||
b) | Position/status | President, Global Vaccines | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
4,180.105 £14.296
| ||||||||
e) | Date of the transaction | 2018-04-12 | ||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr L Miels | ||||||||
b) | Position/status | President, Global Pharmaceuticals | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
9,528.606 £14.296
| ||||||||
e) | Date of the transaction | 2018-04-12 | ||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||||
a) | Name | Mr S Dingemans | ||||||||||
b) | Position/status | Chief Financial Officer | ||||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
a) | Name | GlaxoSmithKline plc | ||||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. | ||||||||||
c) | Price(s) and volume(s) |
| ||||||||||
d) | Aggregated information
Aggregated volume Price |
13,474.367 £14.296
| ||||||||||
e) | Date of the transaction | 2018-04-12 | ||||||||||
f) | Place of the transaction
| London Stock Exchange (XLON | ||||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr N Hirons | ||||||||
b) | Position/status | SVP, Global Ethics & Compliance | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
2,661.111 £14.296
| ||||||||
e) | Date of the transaction | 2018-04-12 | ||||||||
f) | Place of the transaction | London Stock Exchange (XLON) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr D S Redfern | ||||||||
b) | Position/status | Chief Strategy Officer | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
4,909.931 £14.296
| ||||||||
e) | Date of the transaction | 2018-04-12 | ||||||||
f) | Place of the transaction | London Stock Exchange (XLON) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Ms C Thomas | ||||||||
b) | Position/status | SVP, HR | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
5,714.144 £14.296
| ||||||||
e) | Date of the transaction | 2018-04-12 | ||||||||
f) | Place of the transaction | London Stock Exchange (XLON) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||||||||
a) | Name | Mr P C Thomson | |||||||||
b) | Position/status | President, Global Affairs | |||||||||
c) | Initial notification/ amendment | Initial notification | |||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
a) | Name | GlaxoSmithKline plc | |||||||||
b) | LEI | 5493000HZTVUYLO1D793 | |||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| |||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. | |||||||||
c) | Price(s) and volume(s) |
| |||||||||
d) | Aggregated information
Aggregated volume Price |
3,486.288 £14.296
| |||||||||
e) | Date of the transaction | 2018-04-12 | |||||||||
f) | Place of the transaction | London Stock Exchange (XLON) | |||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mrs V A Whyte | ||||||||
b) | Position/status | Company Secretary | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| ||||||||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
602.829 £14.296
| ||||||||
e) | Date of the transaction | 2018-04-12 | ||||||||
f) | Place of the transaction
| London Stock Exchange (XLON) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||||
a) | Name | Mr B McNamara | ||||||||
b) | Position/status | CEO, GSK Consumer Healthcare | ||||||||
c) | Initial notification/ amendment | Initial notification | ||||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
a) | Name | GlaxoSmithKline plc | ||||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||||||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. | ||||||||
c) | Price(s) and volume(s) |
| ||||||||
d) | Aggregated information
Aggregated volume Price |
3,993.911 $40.62
| ||||||||
e) | Date of the transaction | 2018-04-12 | ||||||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||||
a) | Name | Mr D E Troy | ||||||
b) | Position/status | SVP & General Counsel | ||||||
c) | Initial notification/ amendment | Initial notification | ||||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | GlaxoSmithKline plc | ||||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 | ||||||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information
Aggregated volume Price |
3,335.240 $40.62
| ||||||
e) | Date of the transaction | 2018-04-12 | ||||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Mr H Barron | ||||
b) | Position/status | Chief Scientific Officer and President, R&D | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2018-04-12 | ||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||
1. | Details of PDMR/person closely associated with them ('PCA') | |||||
a) | Name | Ms K Terrell | ||||
b) | Position/status | Chief Digital & Technology Officer | ||||
c) | Initial notification/ amendment | Initial notification | ||||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | GlaxoSmithKline plc | ||||
b) | LEI | 5493000HZTVUYLO1D793 | ||||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| ||||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan. | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume Price | n/a (single transaction)
| ||||
e) | Date of the transaction | 2018-04-12 | ||||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | ||||
Related Shares:
Glaxosmithkline